AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05280938 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program
Description: The 8-week Educational Program will be matched in duration, frequency, delivery method, and data collection to the MAAP intervention. Like MAAP, it will be delivered using a hybrid format (virtual Zoom and in person visits).~Sessions will be given in groups by an expert perinatal clinician/educator for all cohorts. Content will be set and delivered consistently across cohorts. Sessions will be audiotaped and rated for achievement of objectives and consistency of delivery. Deviations will be promptly addressed. Subject receipt will be monitored by attendance. Sessions will not include content on stress reduction (yoga, meditation, etc.). Classes will be given in the same setting as the MAAP intervention, at the same time but on a different evening, to avoid crossover (diffusion) of effects.
Study NCT05306028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin or insulin treatment
Description: 1. For patients with new-onset diabetes Fasting blood glucose 7-10 mmol/L, metformin 2 g/day, BID, PO; Fasting blood glucose 10-14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 12 U before breakfast, 8 U; Fasting blood glucose > 14 mmol/L, metformin 1 g/day, BID, PO, Novolin 30R Penfil 16 U before breakfast, 10 U; Adjusting insulin dosage according to the monitor of fasting blood glucose.~2. For patients with history of diabetes Adjusting metformin or insulin dosage according to the monitor of fasting blood glucose.
Study NCT05306912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
Study NCT06775613 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Long-read sequencing
Description: The technology performed belongs to third-generation sequencing strategies and is capable of analysing very long DNA and RNA fragments.
Study NCT06776835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of relative quantitative of small non-coding RNAs
Description: Each participant was enrolled to assess the of relative quantitative of small non-coding RNAs
Study NCT06775275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebellizumab
Description: adebrelimab
Study NCT06775275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab
Study NCT06775275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.
Study NCT04697355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: naringenin and beta carotene
Description: Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks
Study NCT06336707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin / carboplatin
Description: Intravenous infusion
Study NCT06776757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Description: Sintilimab (100mg,150mg, 200mg; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
Study NCT06776757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI)
Description: Sintilimab (Based on Phase 1b recommended dose; Q3W) +Cetuximab (500mg/m²,Q2W)+Chemotherapy（mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI）
Study NCT06776523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders.
Study NCT06776523 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Problem Management Plus
Description: Problem Management Plus (PM+) is a brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.~Additionally, the original five PM+ sessions will be augmented in two ways. First, the participants will receive three 30-45-minutes telephone booster sessions 10, 22, and 34 weeks after the final original PM+ session. The second augmentation strategy involves handouts and homework reminders.
Study NCT06776146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: proteomic profiling
Description: proteomic profiling
Study NCT06379997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen, Hyaluronic Acid, Vitamin C, and Manganese
Description: The Group 1 (G1) will begin taking a dietary supplement the day after enrollment.
Study NCT06379997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular infiltration
Description: Group 2 (G2) will receive three intra-articular injections once per week for 3 weeks, without ultrasound guidance. The route of administration will be intra-articular via the posterior access route.
Study NCT05743829 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue excision as part of routine clinical care
Description: Tissue excision
Study NCT05122182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan Cilexetil
Description: Angiotensin Receptor Blocker (ARB)
Study NCT05122182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan Cilexetil
Description: Angiotensin Receptor Blocker (ARB)
Study NCT05122182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repagermanium
Description: C-C chemokine receptor type 2 (CCR2) antagonist
Study NCT06296797 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control arm: Existing educational website
Description: Information about tubal sterilization currently provided on the Planned Parenthood website
Study NCT06296797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advancing Access Website
Description: A website comparing tubal sterilization to long-acting reversible contraceptives informed by recent patient centered outcomes research.
Study NCT05122182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan Placebo
Description: Angiotensin Receptor Blocker (ARB) placebo
Study NCT05122182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repagermanium Placebo
Description: C-C chemokine receptor type 2 (CCR2) antagonist placebo
Study NCT06776081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss without pharmacotherapy
Description: Adults with obesity participating in the 12-week hypocaloric diet-induced weight loss intervention will be individually counseled by the Clinical and Translational Research Center (CTRC) bionutritionist to consume a hypocaloric diet consistent with current dietary recommendations for weight loss until a 6-10% weight loss is achieved.
Study NCT06775418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound erector spinae plane block
Description: Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group U (15 patients):will receive bilateral US guided single shot ESPB, 30 ml of bupivacaine 0.25% on each side after induction of anesthesia.
Study NCT06775418 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dexamedotomidine infusion after induction of anesthesia
Description: Patients will be subdivided randomly into two groups (15 patients each) using computer generated random numbers with closed envelopes:~Group D (15 patients):will receive the study drug infusion (Dexmedetomidine) after induction of anesthesia.
Study NCT06777342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy intervention
Description: The cognitive behavioral intervention provides sleep-related education 7-14 days before surgery. The educational content should include the following aspects: 1) Establish a consistent bedtime and wake-up time, recommending a sleep schedule from 22:00 to 07:00, and avoid prolonged daytime naps; 2) Optimize the sleep environment by ensuring a quiet setting, turning off lights, and refraining from using mobile phones, computers, and other electronic devices 30 minutes before bedtime; 3) Manage diet by avoiding caffeinated foods such as chocolate, tea, and cola; 4) Engage in appropriate daytime activities as permitted by the patient's condition.
Study NCT06777342 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin intervention
Description: Patients in the melatonin intervention group are required to take an oral melatonin of 5 mg at 30-60 minutes before sleep (administered at 21:00) nightly for 7 to 14 days before surgery. The melatonin was provided by Kangenbei Pharmaceutical Co., LTD. (Hangzhou, Zhejiang, China).
Study NCT06777342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo intervention
Description: Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
Study NCT06777342 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Patients in the placebo group need to take oral placebos of 5 mg at 30-60 minutes (administered at 21:00) before sleep, nightly, for 7 to 14 days before surgery. The placebo is provided by Guangzhou Boji Biomedical Science Park Co., LTD. (Guangzhou, Guangdong, China).
Study NCT06776042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal brushing of the olfactory cleft
Description: Nasal brushing of the olfactory cleft
Study NCT06776042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell testing
Description: Smell testing using the Sniffin' Sticks Test
Study NCT05301842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous)
Study NCT05497011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO Impulse System
Description: After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study NCT05042999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Go Virtual Reality Goggles
Description: Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments. Non pharmacological technique to reduce pain and anxiety during a procedure.
Study NCT06396117 — intervention group
Intervention type: OTHER
Intervention: mTESE (microscopic testicular sperm extraction)
Description: Microdissection Testicular Sperm Extraction (mTESE) is a surgical procedure used to retrieve sperm from the testicles of men with non-obstructive azoospermia (NOA). It involves:~1. Testicular biopsy: Removing a small sample of testicular tissue.~2. Microscopic examination: Examining the tissue under a microscope to identify areas with sperm production.~3. Sperm extraction: Dissecting out individual sperm cells from the testicular tissue.~This technique allows for:~* More accurate identification of sperm-containing areas~* Lower risk of damage to surrounding testicular tissue~* Potential for higher sperm retrieval rates compared to conventional method
Study NCT05572697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive-behavioral therapy for insomnia (dCBT-I)
Description: 6 week sleep intervention delivered via a smartphone app while taking part in inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
Study NCT05572697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Inpatient multimodal rehabilitation for chronic pain lasting 2+2 weeks.
Study NCT05425966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-R-FUERTE
Description: The CLS-R-FUERTE program is a remote school clinician training and comprehensive psychosocial intervention designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). It contains the same evidence-based service components to improve youth attention/behavior as the in-person CLS-FUERTE program; specifically, it features school clinician training by a clinical research team to lead parent skill groups, child skill groups, and teacher consultation in a behavioral classroom management system.
Study NCT06562244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Parents and Teens (PLH)
Description: The PLH program is the core intervention and will be delivered over 6 sessions with adolescents and caregivers, focusing on building positive parent-child relationships, problem-solving skills, stress management, effective limit-setting, and emotional regulation. There will also be a pre-program visit with the facilitator and families prior to the group sessions. Sessions will include both separate and joint activities between adolescents and caregivers. Engagement boosters will be provided during the PLH sessions and are part of the PLH intervention.
Study NCT05301842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous)
Study NCT05301842 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)
Study NCT04402515 — intervention group
Intervention type: DRUG
Intervention: TIO/OLO
Description: Tiotropium/Olodaterol
Study NCT04402515 — intervention group
Intervention type: DRUG
Intervention: ICS
Description: inhaled cortocosteroids
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD)
Description: Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: Epidiolex® doses will be 0.5 mL twice daily during the first seven days of active treatment and 1 mL twice daily (b.i.d.) for the remaining treatment.
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetrahydrocannabinol (THC)
Description: The drug dose will be 2.5 mg b.i.d. during the first 7 days of active treatment, and 5 mg b.i.d. for the following treatment.
Study NCT05269628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CBD
Description: Placebo solution will be taken twice per day, using the same dosing regimen as described for Epidiolex®.
Study NCT05301842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization (TACE)
Description: TACE (chemo and embolic agent injection into the hepatic artery)
Study NCT05301842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib (oral)
Study NCT06775392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bromelain-quercetin gel
Description: bromelain-quercetin gel is prepared from capsules in laboratory
Study NCT06775392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gel
Description: chlorhexidine gel is prepared in laboratory
Study NCT06775392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planing was done with ultra sonic and hand scaling
Study NCT06775665 — intervention group
Intervention type: OTHER
Intervention: No interventions were applied to the patients.
Description: No interventions were applied to the patients.
Study NCT06776796 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Personalized Normative Feedback Intervention Targeting Alcohol Misuse
Description: This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse. It is tailored by the identities chosen by participants including gender, race/ethnicity, and sexual orientation. The intervention is a modified version of an existing evidence-based program, the Brief Alcohol Screening and Intervention for College Students (BASICS) (Dimeff, et. al, 1999).
Study NCT06776796 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental Health and Substance Use Resources
Description: Participants were directed to a website where information regarding mental health and substance use may be found.
Study NCT06776224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of retinal vascular density and visual cognition
Description: During the same visit, we will perform OCT-angiography (10 minutes) and evaluate visual cognition with an eye-tracker (20 minutes)
Study NCT06777264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: single dose of Inaticabtagene autoleucel
Description: Inaticabtagene autoleucel will be transfusioned intravenously at the recommended dose of 0.5×10\^8 (ranging 0.2-0.6×10\^8) viable CAR-T cells.
Study NCT06776536 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound of the bowel endometriosis during operation
Description: This is a prospective, single-arm study aimed at evaluating the efficacy of intraoperative transrectal ultrasound (TRUS) in assessing rectal infiltration depth and length in patients with bowel involvement due to deep infiltrative endometriosis (DIE). The study will include 15-40 female patients aged 18-55, diagnosed with intestinal endometriosis preoperatively using transvaginal ultrasound and MRI, and scheduled for bowel resection.~Preoperative evaluations will include pelvic examination, imaging (TVUS and MRI), and pain assessment using a visual analog scale (VAS). During surgery, TRUS will be used to measure the depth and length of rectal involvement, and findings will be compared with preoperative MRI results.
Study NCT06776770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Phase I: Cohort 1: Adebrelimab 10 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle; Cohort 2: Adebrelimab 1200 mg or 20 mg/kg Q3W plus capecitabine and oxaliplatin (XELOX regimen); 21-day treatment cycle.~Phase II: Adebrelimab (RP2D, Q3W) + (XELOX regimen), with a 3-week (21-day) treatment cycle.~XELOX regimen：Oxaliplatin 130 mg/m2 iv.gtt d1，Capecitabine 1,000 mg/m2 p.o.b.i.d.d1\~14.
Study NCT06562244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping Adolescents Thrive comics
Description: UNICEF's Helping Adolescents Thrive (HAT) comics will be used to guide adolescents through content on improving relationships, handling conflict, understanding emotions, and problem solving. These sessions will be group-based and cover the content in the HAT manual with the adolescents in an interactive format.
Study NCT06562244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Support My Friends
Description: An adapted version of UNICEF's I Support My Friends program will be provided to adolescents by a facilitator in a group-based workshop format over the course of 1 day.
Study NCT05073835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 3 mg
Description: Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).
Study NCT05073835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05631379 — intervention group
Intervention type: OTHER
Intervention: Measurement of body composition with computed tomography (CT)
Description: The cross section of the third lumbar vertebrae in the CT scan images of the patients will be analyzed for assessment of body composition parameters including skeletal muscle area (SMA), muscle radiation attenuation (MRA), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT)
Study NCT05631379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GLIM malnutrition criteria
Description: GLIM criteria (Global Leadership Initiative on Malnutrition) will be applied to assess malnutrition
Study NCT05631379 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EWGSOP2 sarcopenia criteria
Description: EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia